ATE417615T1 - Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen - Google Patents

Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen

Info

Publication number
ATE417615T1
ATE417615T1 AT00971847T AT00971847T ATE417615T1 AT E417615 T1 ATE417615 T1 AT E417615T1 AT 00971847 T AT00971847 T AT 00971847T AT 00971847 T AT00971847 T AT 00971847T AT E417615 T1 ATE417615 T1 AT E417615T1
Authority
AT
Austria
Prior art keywords
alendronate
treatment
calcitriol
pharmaceutical composition
bone
Prior art date
Application number
AT00971847T
Other languages
English (en)
Inventor
Sung An Kang
Kyung Hee Lee
Chung Shil Kwak
Chang Jong Kim
Yong Lee
Original Assignee
Yuyu Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19616174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE417615(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuyu Pharma Inc filed Critical Yuyu Pharma Inc
Application granted granted Critical
Publication of ATE417615T1 publication Critical patent/ATE417615T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00971847T 1999-10-20 2000-10-20 Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen ATE417615T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019990045623A KR100317935B1 (ko) 1999-10-20 1999-10-20 대사성 골질환 치료용 약제조성물 및 이의 제조방법

Publications (1)

Publication Number Publication Date
ATE417615T1 true ATE417615T1 (de) 2009-01-15

Family

ID=19616174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00971847T ATE417615T1 (de) 1999-10-20 2000-10-20 Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen

Country Status (10)

Country Link
US (1) US6835722B1 (de)
EP (1) EP1229917B1 (de)
JP (1) JP4875818B2 (de)
KR (1) KR100317935B1 (de)
CN (1) CN100577172C (de)
AT (1) ATE417615T1 (de)
AU (1) AU1059601A (de)
DE (1) DE60041147D1 (de)
ES (1) ES2316392T3 (de)
WO (1) WO2001028564A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
PT1392325E (pt) * 2001-05-02 2006-10-31 Novartis Ag Metodo de administracao de bifosfonatos por inalacao no tratamento ou na prevencao da reabsorcao ossea e da osteoporose
EP1416919A1 (de) * 2001-07-17 2004-05-12 Teva Pharmaceutical Industries Ltd. Dosierformen für die unmittelbare gastrische freisetzung eines calcium-transport-stimulators in verbindung mit der verzögerten gastrischen freisetzung eines bis-phosphonats
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US20050026871A1 (en) * 2002-07-17 2005-02-03 Moshe Flashner-Barak Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
GB2411116B (en) * 2002-12-16 2009-04-29 Teva Pharma Increasing the bioavailability of alendronate by predose administration of alphacalcidol
DE20321698U1 (de) 2002-12-16 2008-12-24 Teva Pharmaceutical Industries Ltd. Medikament zur Erhöhung der Bioverfügbarkeit von Alendronat oder einem anderen Bisphosphonat durch Verabreichen einer Vordosis eines Vitamin-D-Derivats
PL1656372T3 (pl) 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
CA2539359A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
NZ546349A (en) * 2003-09-29 2010-03-26 Cipla Ltd Pharmaceutical formulation with improved stability
CA2555406A1 (en) 2004-02-19 2005-09-01 Teva Pharmaceutical Industries, Ltd. Improved therapy using a combination of raloxifene and alendronate
FR2871699A1 (fr) * 2004-06-17 2005-12-23 Galderma Sa Composition de type emulsion inverse contenant du calcitrol et du 17-propionate de clobetasol, et ses utilisations en cosmetiques et en dermatologie
WO2006046100A1 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Pharmaceutical composition of alendronic acid
WO2006135915A2 (en) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
PL1734251T3 (pl) * 2005-06-17 2007-05-31 Magneti Marelli Powertrain Spa Wtryskiwacz paliwa
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
US20080076742A1 (en) * 2005-10-31 2008-03-27 Wisconsin Alumni Research Foundation Methods and compositions for treating diseases associated with neovascualrization
AU2007281094A1 (en) * 2006-08-02 2008-02-07 Board Of Regents Of The University Of Nebraska Drug carriers, their synthesis, and methods of use thereof
KR100822133B1 (ko) * 2006-11-06 2008-04-15 한미약품 주식회사 비타민 ｄ 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제
CA2732863A1 (en) * 2008-08-01 2010-02-04 Dong Wha Pharmaceutical Co., Ltd. A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt
KR20100014090A (ko) * 2008-08-01 2010-02-10 동화약품주식회사 벤즈아미딘 유도체 또는 이의 염, 및 비스포스포네이트를 포함하는 골다공증의 예방 또는 치료용 약학 조성물
US7964584B2 (en) 2008-08-01 2011-06-21 Dong Wha Pharmaceutical Co., Ltd. Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivatives or their salts, and alendronic acid or its salt
US20100158998A1 (en) * 2008-12-23 2010-06-24 Michael Fox Formulations comprising vitamin d or derivatives thereof
WO2011024208A1 (en) * 2009-08-24 2011-03-03 Colotech A/S Combination dosage form with acetylsalicylic acid, calcitriol and calcium
KR101102364B1 (ko) 2009-09-18 2012-01-03 한림제약(주) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
CN102210697B (zh) * 2010-04-02 2013-05-22 秦引林 用于治疗代谢性骨病的药物组合
CN102210696A (zh) * 2010-04-02 2011-10-12 秦引林 一种含唑来膦酸的药物组合
EP2468265A3 (de) * 2010-12-04 2013-01-02 DEEF Pharmaceutical Industries Co. Homogene Zubereitungen mit Vitamin D
CN103202848A (zh) * 2013-03-21 2013-07-17 青岛正大海尔制药有限公司 用于治疗骨质疏松的药物组合物
PT106978A (pt) 2013-05-31 2014-12-02 Tecnimede Sociedade Tecnico Medicinal S A Composição sólida oral contendo ácido ibandrónico e vitamina d
KR101983654B1 (ko) * 2018-07-24 2019-05-29 한국과학기술원 Cfc 증후군 환자의 발달 저해를 완화할 수 있는 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR884628A (fr) 1942-03-25 1943-08-23 Cie Ingersoll Rand Procédé de bourrage des trous de mines et appareil pour sa mise en oeuvre
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
JPH05124966A (ja) * 1991-10-31 1993-05-21 Doujin Iyaku Kako Kk カルシトリオール固形製剤
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
JP3566984B2 (ja) 1994-06-02 2004-09-15 帝人株式会社 骨形成促進剤
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
EP0809502A4 (de) * 1995-02-17 2001-12-05 Merck & Co Inc Verfahren zur verminderung des risikos nicht-vertebraler knochenbrüche
IL118422A0 (en) * 1995-06-02 1996-09-12 Merck & Co Inc Use of alendronate for the prevention of osteoporosis
US5952317A (en) * 1995-09-21 1999-09-14 Wisconsin Alumni Research Foundation Calcitriol derivatives and their uses
NZ319819A (en) * 1995-09-21 2000-02-28 Wisconsin Alumni Res Found Calcitriol derivatives and their uses
JPH1160489A (ja) * 1997-06-12 1999-03-02 Teijin Ltd 骨粗鬆症予防剤または治療剤
US6410782B1 (en) * 1997-07-09 2002-06-25 Geange Ltd. Diphosphonic acid salts for the treatment of osteoporosis
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법

Also Published As

Publication number Publication date
ES2316392T3 (es) 2009-04-16
EP1229917B1 (de) 2008-12-17
KR100317935B1 (ko) 2001-12-22
WO2001028564A1 (en) 2001-04-26
JP4875818B2 (ja) 2012-02-15
US6835722B1 (en) 2004-12-28
JP2003514776A (ja) 2003-04-22
CN1420777A (zh) 2003-05-28
EP1229917A1 (de) 2002-08-14
DE60041147D1 (de) 2009-01-29
EP1229917A4 (de) 2005-08-03
KR20010037885A (ko) 2001-05-15
CN100577172C (zh) 2010-01-06
AU1059601A (en) 2001-04-30

Similar Documents

Publication Publication Date Title
ATE417615T1 (de) Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen
Reid Anti-resorptive therapies for osteoporosis
MXPA04012998A (es) Modulares de receptores nucleares de hormonas esteroideas triciclicos.
US10143685B2 (en) Parenteral and topical compositions for pain
CA2151240A1 (en) Biophosphonate/estrogen therapy for treating and preventing bone loss
ATE210643T1 (de) Prostaglandin-analoga zur behandlung von osteoporose
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
RU2008103617A (ru) Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
CA2457840A1 (en) Hdl for the treatment of stroke and other ischemic conditions
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
CA2294101A1 (en) A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
TW200603816A (en) Risedronate compositions and their methods of use
DE60043346D1 (de) Methoden zur hemmung der aktivität der osteoklasten
HK1087039A1 (en) Use of biphosphonate in preparing medical kit and a kit used for increasing bone mass
US6399592B1 (en) Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
RU2007117492A (ru) Применение органических соединений
JP4931306B2 (ja) 骨形成を安全に促進させる医薬複合剤
EP1117410B1 (de) Verwendung von bisphosphonsaüre derivaten zur herstellung eines arzneimittels zur behandlung von lahmen
MX2013010622A (es) Composiciones y métodos para el tratamiento de enfermedades y transtornos relacionados con el tejido musculoesquelético utilizando complejos de análogo de citrato de ion metálico.
JPH061721A (ja) 疼痛処置剤、及び疼痛軽減作用増強剤
GB2355930A (en) Injection of pantothenic acid for relief of pain in joints
WO2005074944A1 (en) Use of sodium neridronate to promote new bone formation
JP5300943B2 (ja) 骨形成を安全に促進させる医薬複合剤
AU2006311227B2 (en) Use of clodronic acid for the treatment of navicular syndrome

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties